Evgen Pharma PLC Directorate Change (4037B)

TIDMEVG

RNS Number : 4037B

Evgen Pharma PLC

03 April 2017

 
 For immediate release   3 April 2017 
 

Evgen Pharma plc

("Evgen Pharma" or "the Company")

Directorate Change

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that Non-Executive Director Mark Wyatt is stepping down from the Board with immediate effect.

Mark joined the Board of Evgen Limited, the predecessor to Evgen Pharma, in June 2012, as a representative of the RisingStars Growth Fund II, a fund managed by Enterprise Ventures Group Limited, one of the Company's original venture capital investors.

Mark was instrumental in the early development of Evgen Pharma and he was closely involved in the AIM flotation. With that work complete, he intends to focus his directorships on earlier stage companies in his investment portfolio.

Barry Clare, Evgen Pharma's Chairman, commented:

"On behalf of the board, I would like to extend sincere thanks to Mark Wyatt for his very substantial contribution to the early development and to the IPO of Evgen Pharma. We wish him every success with his current and future business interests."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

 
 Evgen Pharma plc                              c/o +44 (0) 20 
  Dr Stephen Franklin, CEO                          7466 5000 
  www.evgen.com 
 
 Buchanan 
  Mark Court, Sophie Cowles, Stephanie             +44 (0) 20 
  Watson                                            7466 5000 
 
 Northland Capital Partners Limited 
  Matthew Johnson, Gerry Beaney, Margarita 
  Mitropoulou (Corporate Finance) 
  John Howes and Rob Rees (Corporate               +44 (0) 20 
  Broking)                                          3861 6625 
 
 

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Evgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information please visit: www.evgen.com

Or for recent commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOALLFLVSLIVIID

(END) Dow Jones Newswires

April 03, 2017 09:15 ET (13:15 GMT)